Dr. Vickery, an Atlanta native, is a pediatric allergist-immunologist. He serves as Chief of Allergy and Immunology and the Director of the Food Allergy Program at Children’s Healthcare of Atlanta and Associate Professor of Emory University School of Medicine.
Prior to joining Children’s, Dr. Vickery held faculty positions at Duke University School of Medicine and the University of North Carolina-Chapel Hill School of Medicine. While working at the University of North Carolina School of Medicine, he led a group that was first to show sustained unresponsiveness can occur after peanut OIT. He subsequently demonstrated that early treatment of peanut-allergic preschool children with OIT is safe and leads to better outcomes. Most recently at UNC, Dr. Vickery led the development of an investigational treatment for peanut allergy as a Senior Medical Director at Aimmune Therapeutics.
Dr. Vickery has published more than 50 papers in leading journals and has presented his work at national and international meetings. He has also contributed to the development of national food allergy treatment guidelines. Dr. Vickery has received several awards for clinical care as well as research awards from the American Academy of Allergy, Asthma and Immunology (AAAAI), the American College of Allergy, Asthma and Immunology, and the British Society of Allergy and Clinical Immunology.
Dr. Vickery’s research efforts focus on understanding the pathophysiology of food allergies and anaphylaxis as well as developing new therapies to treat them.
Focus of Practice
Areas of Interest
- Atopic dermatitis
- Eosinophilic disease
- Food allergies
- General pediatric allergy and immunology
In the News
Eight percent of children are affected by food allergies and it can be tough, but a new breakthrough study by Children's Healthcare of Atlanta could bring comfort to families. Director of Children's Food Allergy Program and study co-author Brian Vickery sits down with Alyse Eady to talk about the potential treatment.
Children’s Healthcare of Atlanta says young children suffering from peanut allergies may soon have a new treatment option, according to a study recently published in The New England Journal of Medicine.
Children’s Healthcare of Atlanta was instrumental in a first-of-its-kind study for children ages one to four, to help mitigate peanut allergies. The breakthrough study reveals promising results for a skin patch that could protect patients from accidental exposures. The patch is about the size of a quarter and placed on the back like a Band-Aid.
Atlanta News First
Researchers at Children’s Healthcare of Atlanta recently participated in the international, multicenter, Phase 3 EPITOPE trial to determine the safety and efficacy of epicutaneous, meaning “on the skin”, immunotherapy (EPIT) for children ages one to three years of who have been diagnosed with peanut allergy.
Brian Vickery, MD, Director of the Food Allergy Program at Children’s, is a co-author of this publication in the New England Journal of Medicine, having participated as a site Principal Investigator in this global study. The results show that 12 months of treatment with DBV Technologies’ Viaskin™ Peanut patch desensitized toddlers to peanuts, decreasing the chance of experiencing an allergic reaction after an accidental peanut exposure.
Study results suggest that treatment can protect some children against accidental exposure to or ingestion of a very small amount of peanuts or peanut products.
A new study found that gradually exposing children to peanut protein could increase their tolerance.
Results from a new study may lead to approval of what could be the first drug that ameliorates potentially deadly reactions in children with severe peanut allergies.
New York Times